The weight-loss and diabetes drugs accounted for nearly two-thirds of Lilly’s $19.8 billion quarterly revenue, accelerating growth.
Eli Lilly’s Mounjaro and Zepbound generated $12.8 billion in revenue during Q1 2026, representing nearly 65% of the company’s $19.8 billion total revenue. The drugs’ performance underscores their dominance in Lilly’s portfolio as demand surges.
Mounjaro, used for type 2 diabetes, saw revenue jump 125% year-over-year to $8.7 billion, while Zepbound, marketed for weight loss, grew 80% to $4.2 billion. Combined revenue for the drugs more than doubled from $6.2 billion in Q1 2025, with sequential growth in each quarter.
For full-year 2025, the franchise contributed $36.5 billion, over half of Lilly’s $65.2 billion total revenue. Mounjaro’s growth rate accelerated from 99% in 2025 to 125% in Q1 2026, signaling sustained momentum.